Cor Therapeutics Inc. (CORR) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cor Therapeutics Inc. (CORR)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Edscharp who wrote (414)	4/26/1999 11:52:00 AM
From: LLCF	Read Replies (2) of 712

Thank-you, there we go: <The company has increased estimates for Integrilin sales to $65 - $70 million this year, $175 - $200 million for 2000, and $300 - $350 million for 2001.> Well, there you go, based on these numbers the stock seems way cheap just based on one product! What about their oral version in phase2 for stroke and ACS? What about Intergilin phase2 for heart attack indication? You know what, someone will probably buy these guys IMO. DAK

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next